Buffett Brain · Research note
Score updated 26 Sept 2026
HALO· Healthcare
Halozyme Therapeutics
Halozyme's ENHANZE platform drives high margins and ROIC, but negative EPS growth raises durability concerns.
Buffett fit
Strong fit
Owner
82
Durability
56
Management
80
Price
64
Score updated 26 Sept 2026
Buffett's checklist
Each number against Buffett's bar, and where it ranks among Healthcare stocks in our database.
How much profit the business makes on each dollar invested in it. Higher is better.
What is left of each sale after the cost of making the product. A high number often means pricing power.
The cash the business earns for its owners, compared with the price of the whole company.
How fast sales grew each year over the last five years.
How many years of today's profit you pay for at today's price. Lower means cheaper.
How much the company owes compared with what it owns outright. Lower is safer.
The four pillars
How the business measures up on each of Buffett's four tests.
Owning 100% of Halozyme would mean relying on its ENHANZE platform's continued adoption by pharmaceutical partners.
The full reasoning comes with a free account.
The durability of Halozyme hinges on maintaining its competitive edge in drug delivery technology.
The full reasoning comes with a free account.
Management has effectively reduced the share count by 3.92% annually, enhancing shareholder value.
The full reasoning comes with a free account.
With a of 23.3 and an yield of 7.91%, Halozyme is priced at a premium, reflecting market optimism.
The full reasoning comes with a free account.
Free account
Read the full Halozyme Therapeutics analysis free
- The full reasoning behind all four pillars
- The 5-year price target and the return it implies
- What would change the call
- Graham, Lynch and Greenblatt on the same stock
3 full analyses a week · no card needed
For and against
The strongest points on each side, with the numbers behind them.
In its favor
7- 1 of 57.0% is top-quintile in the healthcare sector.
- 2 of 23.6% places it well above the sector's top-quintile cutoff of 10.7%.
- 3Interest coverage ratio of 45.0 indicates strong ability to meet financial obligations.
- 4Share count has decreased by 3.92% annually, showing effective .
Concerns
6- 1EPS CAGR of -1.98% over five years indicates declining earnings.
- 2 of 76.9% is below the sector's top-quintile cutoff of 77.9%.
- 3P/B ratio of 36.97 suggests aggressive market valuation.
- 4Debt/Equity ratio of 9.76 could be a concern if earnings volatility increases.
Price history
$125+227.1%· 5-year return
Weekly closing prices. Touch or hover the line for a date.
The business
How the business works
Halozyme Therapeutics operates a biopharma technology platform centered on its ENHANZE drug delivery technology. The company licenses this platform to major pharmaceutical companies, generating revenue through royalties and milestone payments. With a revenue of $1.4B and a net income of $316.89M, it enjoys a high net margin of 23.1%. The business model benefits from the recurring nature of licensing agreements, providing stable cash flows.
How this analysis has moved
The call has held across 5 reviews.
Sep 27, 2026 → Oct 22, 2026
What other investors would say
The same company, judged by three other documented playbooks.
Keep researching
Similar companies in Healthcare
Free weekly email
Liked the read on HALO? Get the next ones on Monday.
Every Monday: the stocks most of the seven investors newly agree on. One email, unsubscribe any time.
Research, not investment advice.
See the Buffett analysis of Halozyme Therapeutics
The score, the checklist and the full reasoning open with a free account. You get 3 full analyses a week, and this stock is the first one. No card needed.
Create a free account3 full analyses a week · no card needed
Already have an account? Sign in